Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-07-29
1999-06-29
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514188, 514189, A61K 31555
Patent
active
059168854
ABSTRACT:
A locally administrable topical pharmaceutical composition is provided for prevention or treatment of skin conditions associated with hyperproliferation of skin cells and/or an immunologically mediated disorder, e.g., psoriasis, atopical dermatitis, contact dermatitis, seborrhoeic dermatitis, lupus and the like. The composition contains a topical carrier and spirogermanium or a structurally related azaspirane. Also provided are methods for using the novel composition and laminated patches which may be applied to the skin to administer the composition thereto.
REFERENCES:
patent: 3825546 (1974-07-01), Rice
patent: 4291030 (1981-09-01), Mulinos
patent: 4468393 (1984-08-01), Geschickter
patent: 4654333 (1987-03-01), Tenoso
patent: 5064835 (1991-11-01), Bochis et al.
patent: 5246706 (1993-09-01), Chiang et al.
Jack L. Arbiser (1996), "Angiogenesis and the Skin: a Primer," J. Am Acad Dermatol U.S., 34(3):486-497.
Alison M. Badger et al. (1990), "Antiarthritic and Suppressor Cell Inducing Activity of Azaspiranes: Structure-Function Relationships of a Novel Class of Immunomodulatory Agents," J. Med. Chem 33:2963-2970.
Elizabeth Eisenhauer et al. (1985), "A Phase II Study of Spirogermanium in Patients with Metastatic Malignant Melanoma," Investigational New Drugs 3:303-305.
Bridget T. Hill et al (1982), "Cytotoxic Effects and Biological Activity of Dichloride (NSC 192965; Spirogermanium) in Vitro," Cancer Research 42(7):2852-2856.
Daniel N. Sauder et al. (1980), "Suppressor Cell Function in Psoriasis," Arch. Dermatol. 116:51-55.
Badger et al., "Generation of Suppressor Cells in Normal Rats by Treatment with Spirogermanium, a Novel Heterocyclic Anticancer Drug," Immunopharmacology 10:201-207 (1985).
Badger et al., "Antiarthritic and Suppressor Cell Inducing Activity of Azaspiranes: Structure-Function Relationships of a Novel Class of Immunomodulatory Agents," J. Med. Chem. 33:2963-2970 (1990).
Berardesca et al., "Non-invasive Evaluation of Topical Calcipotriol versus Clobetasol in the Treatment of Psoriasis," Acta Derm Venereol (Stokh) 74:302-304 (1994).
DiMartino et al., "Antiarthritic and Immunoregulatory Activity of Spirogermanium," J. Pharmacol. and Exper. Therapeutics 236(1):103-110.
Elias et al., "A Controlled Trial of Topical Propylthiouracil in the Treatment of Patients with Psoriasis," J. Amer. Acad. Dermatol. 31(3):455-458.
Highton et al., "Calcipotriene Ointment 0.005% for Psoriasis: A Safety and Efficacy Study," J. Amer. Acad. Dermatol. 32:(1):67-72 (1995).
Mirabelli et al., "Pharmacological Activities of Spirogermanium and Other Structurally Related Azaspiranes: Effects on Tumor Cell and Macrophage Functions," Anti-Cancer Drug Design 3:231-242 (1989).
Rice et al., "Spirans XXII. Synthesis of 4,4-Dialkyl-4-germacyclo-hexanone 11:1041-1047 (1974).
Schein, P.S. et al., "Phase I Clinical Trial of Spirogermanium," Cancer Treatment Reports, vol. 64, No. 10-11, pp. 1051-1056 (Oct./Nov. 1980).
Slavik et al., "Spirogermanium: A New Investigational Drug of Novel Structure and Lack of Bone Marrow Toxicity," Investigational New Drugs 1:225-234 (1983).
Fay Zohreh
Maher David W.
Reed Dianne E.
LandOfFree
Topical administration of certain azaspiranes to prevent or trea does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical administration of certain azaspiranes to prevent or trea, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical administration of certain azaspiranes to prevent or trea will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1375571